These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18690928)

  • 1. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.
    Coulter DM
    Drug Saf; 2002; 25(6):433-9. PubMed ID: 12071780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 1998 Mar; 7(2):79-90. PubMed ID: 15073731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2000 Jul; 9(4):273-80. PubMed ID: 19025828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena).
    Zhou L; Harrison-Woolrych M; Coulter DM
    Pharmacoepidemiol Drug Saf; 2003; 12(5):371-7. PubMed ID: 12899110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres.
    Harrison-Woolrych M; Härmark L; Tan M; Maggo S; van Grootheest K
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1065-72. PubMed ID: 22315148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Maggo S; Tan M; Savage R; Ashton J
    Drug Saf; 2012 Jan; 35(1):33-43. PubMed ID: 22149418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking pharmacovigilance with pharmacogenetics.
    Clark DW; Donnelly E; Coulter DM; Roberts RL; Kennedy MA
    Drug Saf; 2004; 27(15):1171-84. PubMed ID: 15588114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark DW; Strandell J
    Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
    Harrison-Woolrych M; Herbison P; McLean R; Ashton J; Slattery J
    Drug Saf; 2005; 28(5):435-42. PubMed ID: 15853444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
    Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hair loss with use of the levonorgestrel intrauterine device.
    Paterson H; Clifton J; Miller D; Ashton J; Harrison-Woolrych M
    Contraception; 2007 Oct; 76(4):306-9. PubMed ID: 17900442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme.
    Hill GR; Harrison-Woolrych M
    N Z Med J; 2008 Oct; 121(1283):68-75. PubMed ID: 18841187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription-event monitoring and reporting of adverse drug reactions.
    Heeley E; Riley J; Layton D; Wilton LV; Shakir SA
    Lancet; 2001 Dec; 358(9296):1872-3. PubMed ID: 11741629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.
    Star K; Sandberg L; Bergvall T; Choonara I; Caduff-Janosa P; Edwards IR
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):680-689. PubMed ID: 30767342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.